These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8257744)

  • 1. Fluorimetric determination of tauromustine (a novel antitumour agent) in formulations and biological fluids.
    Walash MI; Belal F; Metwally ME; Hefnawy MM
    J Pharm Biomed Anal; 1993 Aug; 11(8):777-80. PubMed ID: 8257744
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of tauromustine and its demethylated metabolites in plasma and urine.
    Polacek J; Gustafsson B; Brandin S; Ottersgård-Brorsson A
    J Chromatogr; 1990 Mar; 526(1):151-7. PubMed ID: 2341526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of tauromustine, a nitrosourea-based antitumour agent, in plasma by high-performance liquid chromatography.
    Polacek J; Gunnarsson PO; Brandin S
    J Chromatogr; 1988 Mar; 425(2):424-8. PubMed ID: 3372655
    [No Abstract]   [Full Text] [Related]  

  • 4. Quantitative determination of 1-2(chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea in blood and urine of man.
    Nakajima O; Yoshida Y; Kubota T; Takemasa Y; Koyama Y
    J Chromatogr; 1982 May; 229(2):481-6. PubMed ID: 6212589
    [No Abstract]   [Full Text] [Related]  

  • 5. Degradation of tauromustine (TCNU) in aqueous solutions.
    Loftsson T; Baldvinsdóttir J
    Acta Pharm Nord; 1992; 4(3):129-32. PubMed ID: 1418640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications.
    Whittle IR; MacPherson JS; Miller JD; Smyth JF
    J Neurosurg; 1990 May; 72(5):721-5. PubMed ID: 2157825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous determination of desloratadine and montelukast sodium using second-derivative synchronous fluorescence spectrometry enhanced by an organized medium with applications to tablets and human plasma.
    Ibrahim FA; El-Enany N; El-Shaheny RN; Mikhail IE
    Luminescence; 2015 Jun; 30(4):485-94. PubMed ID: 25209552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
    Smyth JF; Hardcastle JD; Denton G; Alderson D; Grace RH; Mansi JL; Yosef HM; Nordle O; Lauri H; Wählby S
    Ann Oncol; 1995 Nov; 6(9):948-9. PubMed ID: 8624301
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of tauromustine in disseminated malignant melanoma.
    Gjedde SB; Mouridsen HT; L-Madsen E; Jensen NV; Blomquist E; Bergh J; Söderberg M; Wählby S
    Eur J Cancer; 1994; 30A(4):566. PubMed ID: 8018421
    [No Abstract]   [Full Text] [Related]  

  • 10. Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro.
    Hartley-Asp B
    Mutagenesis; 1992 Nov; 7(6):427-31. PubMed ID: 1474918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid chromatographic determination of taurine in vitamin premix formulations.
    Rao GN
    J Assoc Off Anal Chem; 1987; 70(5):799-801. PubMed ID: 3680112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of tauromustine in cancer patients. Phase I studies.
    Gunnarsson PO; Vibe-Petersen J; Macpherson JS; Warrington PS; Polacek J; Ellman M; Hansen HH; Smyth JF
    Cancer Chemother Pharmacol; 1989; 23(3):176-80. PubMed ID: 2924375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An eco-friendly stability-indicating spectrofluorimetric method for the determination of two anticancer stereoisomer drugs in their pharmaceutical preparations following micellar enhancement: Application to kinetic degradation studies.
    El-Kimary EI; El-Yazbi AF
    Spectrochim Acta A Mol Biomol Spectrosc; 2016 Jun; 163():145-53. PubMed ID: 27045788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of a novel nitrosourea, tauromustine, in the rat.
    Seidegård J; Grönquist L; Gunnarsson PO
    Biochem Pharmacol; 1990 May; 39(9):1431-6. PubMed ID: 2334443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactions of 1-(2-chloroethyl)-1-nitroso-3-(3-pyridylmethyl)urea Narom-oxide with several biological model compounds.
    Miyahara M; Sueyoshi S; Kamiya S
    Chem Pharm Bull (Tokyo); 1985 Dec; 33(12):5557-61. PubMed ID: 3833395
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I study of tauromustine administered in a weekly schedule.
    Gjedde SB; Mouridsen HT; L-Madsen E; Jensen NV; Blomquist E; Bergh J; Söderberg M; Wählby S
    Eur J Cancer; 1993; 29A(13):1901-2. PubMed ID: 8260251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of derivatization reactions with adsorptive stripping voltammetry for determining fotemustine in biological samples.
    Díaz De Guereñu MM; Barrio RJ; Arranz A; Arranz JF
    J Pharm Biomed Anal; 1992 Jul; 10(7):481-6. PubMed ID: 1420472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations.
    Double JA; Bibby MC; Loadman PM; Bloomer JC
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1355-60. PubMed ID: 3181256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antitumor effect of a novel nitrosourea, tauromustine, at intravenous administration in rat. Cure of hepatomas.
    Roos G; el Hag IA; Christensson PI; Stenram U
    Anticancer Res; 1991; 11(5):1763-6. PubMed ID: 1837442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea in plasma by negative chemical ionization mass spectrometry.
    Smith RG; Cheung LK; Feun LG; Loo TL
    Biomed Mass Spectrom; 1983 Jul; 10(7):404-7. PubMed ID: 6616018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.